Methods of identifying genomic and proteomic biomarkers for cystic fibrosis, arrays comprising the biomarkers and methods of using the arrays

• US 20060292562A1
• Filed: 05/29/2003
• Published: 12/28/2006
• Est. Priority Date: 05/29/2002
• Status: Abandoned Application

• Current Assignee: National Institutes of Health (NIH) (Government of the United States of America), Henry M Jackson Foundation For The Advancement of Military Medicine Incorporated, Johns Hopkins University
• Original Assignee: National Institutes of Health (NIH) (Government of the United States of America)
• Inventors: Mueller, Greg, Jacobwitz, David, Eidelman, Ofer, Zeitlin, Pamela, Pollard, Harvey B., Srivastava, Meera, Guggino, William
• Application Number:
  US10/515,844
• Publication Number:
  US 20060292562A1
• Time in Patent Office: Days
• US Class Current: 435/6.17
• CPC Class Codes: C12N 9/16 acting on ester bonds (3.1)
• CPC Class Codes: C12Q 1/6813 Hybridisation assays
• CPC Class Codes: C12Q 1/6837 using probe arrays or probe chips C12Q1/6874 takes precedence
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2563/101 radioactivity, e.g. radioactive labels
• CPC Class Codes: C12Q 2600/158 Expression markers

Abstract

Cystic fibrosis (CF) is the most common fatal autosomal recessive disease in the U.S. and is principally caused by the DF508 mutation the CFTR gene. The principal site of morbidity and mortality for this disease is the lung. We have used genomic and proteomic methods to identify ubiquitin carboxy terminal hydrolase-1 (UCHL1) as a biomarker for cystic fibrosis. Both gene expression and cognate protein expression are massively upregulated in CF lung epithelial cells. We suggest that this gene can be useful in the assembly of a diagnostic or prognostic chip for CF, or as a target for therapeutic intervention.

Claims

1. A method of determining the level of expression of a population of proteins in a first cell comprising:

growing the first cells in a medium comprising radio-labeled amino acids such that the radio-labeled amino acid is incorporated into the proteins;

lysing the first cells;

placing the first cell lysate on a first gel;

separating the proteins in the first cell lysate using 2-D gel electrophoresis; and

imaging the first gel using autoradiography.

2. The method of claim 1, wherein the first cells have a mutated form of the CFTR gene.

3. The method of claim 1, wherein the cells have the wildtype CFTR gene.

4. The method of claim 2, further comprising:

growing second cells having the wildtype CFTR gene in methionine-free medium supplemented with 35[S] methionine;

lysing the second cells;

placing the second cell lysate on a second gel;

separating the proteins in the second cell lysate using 2-D gel electrophoresis;

imaging the second gel using autoradiography; and

comparing the images for the first and second cells.

5. The method of claim 4, wherein the first cells are IB-3 cells and wherein the second cells are IB-3/S9 cells.

6. The method of claim 4, further comprising:

identifying proteins that exhibit different levels of expression between the first and second cells.

7. The method of claim 6, further comprising:

identifying the nucleotide sequence of aptamers which bind the identified proteins.

8. The method of claim 7, further comprising:

constructing an array comprising aptamers having the identified sequences attached to a solid support.

9. The method of claim 1, wherein the radio-labeled amino acid is 35[S] methionine.

10. The method of claim 1, wherein the population of proteins is the proteome of the first cell.

18. The array of claim 1, wherein the markers are selected from the group consisting of:

NMDA Receptor subunit epsilon 2 (NMDAR2B);

Voltage gated potassium channel protein KV12;

Leukocyte common antigen (L-CA;

CD45 antigen);

Adenosine A1 Receptor (ADORA1);

CD40 Receptor Associated Antigen (CRAF-1);

Tumor Necrosis Factor alpha;

parkin;

glutathione S-Transferase A1 (GTH1);

Signal transducer and activator of transcription 1 (STAT1);

ergB;

DNA binding protein HIP116;

Bone Morphogenic Protein3 (BMP3);

translin;

PI3-Kinase, p110;

IL-2Rgamma;

cmyc oncogene;

lissencephalin X;

cAMP Response Element Binding Protein (CREBBP);

casein kinase 1 gamma 2;

ribosomal protein S6 kinase II alpha 3;

macrophage-specific colony stimulating factor (MCSF);

cellular retinoic acid binding protein II (CRABP2);

cadherin 3 (P-cadherin);

basic transcription factor 62-kDa subunit (BTF2);

placenta growth factor 1;

placenta growth factor 2;

FUSE binding protein;

leukemia inhibitory factor (LIF;

HILDA);

beta-interferon gene positive regulatory domain 1 binding factor (BLIMP1);

interferon consensus sequence-binding protein (ICSBP);

calcium activated potassium channel HSK1;

NFkB, p100 (NFkB, p52);

IL-17;

GABA Receptor epsilon subunit [GABA(A)Receptor];

RAB3B;

p16-INK4;

frizzled;

OCT-2;

IL-4;

Matrix metalloproteinase 12 (MMP12);

G-Protein activated inward rectifier Potassium channel 3 (KIR3.3);

zinc finger protein 91;

DNA Repair protein XRCC1;

RAG2;

IL-8;

actophilin;

coactosin;

UCH-L1 and combinations thereof.

19. A method comprising:

removing cells from a patient;

lysing the cells; and

contacting the cell lysate with an array as set forth in claim 1.

20. The method of claim 19, further comprising imaging the array.

21. The method of claim 19, wherein the patient has not been diagnosed with cystic fibrosis and wherein the method is a method for diagnosing cystic fibrosis.

22. The method of claim 20, wherein the patient has not been diagnosed with cystic fibrosis and wherein the method is a method for diagnosing cystic fibrosis.

23. The method of claim 22, further comprising comparing the image of the array with a control image made by imaging an array contacted with a control composition comprising the lysate of a cell having the wildtype CFTR gene.

24. The method of claim 19, wherein the patient has been diagnosed with cystic fibrosis and wherein the method is a method for determining the prognosis of the disease.

25. The method of claim 19, wherein the patient is undergoing treatment for cystic fibrosis and wherein the method is a method for determining the effectiveness of the treatment.

26. The method of claim 20, wherein the patient is undergoing treatment for cystic fibrosis and wherein the method is a method for determining the effectiveness of the treatment.

27. The method of claim 26, further comprising comparing the image of the array with a control image made by imaging an array contacted with a control composition comprising the lysate of a cell sample removed from the patient during an earlier stage of the treatment.

28. A method comprising:

contacting cells having a mutated form of the CFTR gene with a composition comprising a test compound;

lysing the cells;

contacting the cell lysate with an array as set forth in claim 1.

29. The method of claim 28, further comprising imaging the array.

30. The method of claim 28, further comprising comparing the image of the array with a control image made by imaging an array contacted with a control composition which does not include the test compound.

11. An array comprising:

a plurality of different probes disposed on a surface of a solid support, wherein each of the different probes bind to a different marker for cystic fibrosis.

12. The array of claim 11, wherein the plurality of different probes include probes for UCHL-1 and IL-8.

13. The array of claim 11, wherein the probes and markers are nucleic acids.

14. The array of claim 11, wherein the probes comprise cDNA or oligonucleotide probes.

15. The array of claim 11, wherein the markers comprise mRNA markers.

16. The array of claim 11, wherein the probes comprise nucleic acid probes and the markers comprise protein markers.

17. The array of claim 15, wherein the probes comprise aptamers.